Nilofer Azad, MD
Medical Oncology · Baltimore, MDNPI 1568635712
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $116,093 of the $142,835 with a category attached, or 81.3%. 14 manufacturers reported payments, led by AstraZeneca at 24.1% of the total. 2025 is the largest year on record at $47,557, more than ten times the $2,913 reported in 2019. Among medical oncology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $1275.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$34K
- E.r. Squibb & Sons, L.L.C.$25K
- Incyte Corporation$19K
- Taiho Oncology, Inc.$18K
- GSK$14K
- Mirati Therapeutics, Inc.$14K
- plus $18K from 8 others
Across 457 payments — averaging $13,974 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$1.3M
- Incyte Corporation$882K
- E.r. Squibb & Sons, L.L.C.$750K
- Otsuka Pharmaceutical Co., Ltd.$660K
- Merck$606K
- EMD Serono, Inc.$483K
- plus $1.7M from 14 others
What the payments were for
- Consulting fees$116,09381%
- Speaking & faculty fees$11,8508%
- Travel & lodging$12,7089%
- Food & beverage$2,1421%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $34,397 |
| E.r. Squibb & Sons, L.L.C. | 18 | $25,353 |
| Incyte Corporation | 21 | $19,083 |
| Taiho Oncology, Inc. | 16 | $18,234 |
| GSK | 4 | $14,250 |
| Mirati Therapeutics, Inc. | 10 | $13,653 |
| Merck | 4 | $6,495 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $5,648 |
| Eli Lilly | 6 | $3,574 |
| Astrazeneca UK Limited | 1 | $1,713 |
| Partner Therapeutics, Inc. | 3 | $247 |
| Genentech, Inc. | 1 | $95 |
| Jazz Pharmaceuticals Inc. | 1 | $51 |
| Tempus AI, Inc | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,835 in reported general payments places this provider in the 90th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 20 | $130 |
| Ondansetron Hcl | 13 | $107 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Julie BrahmerBaltimore$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.